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Stem cell senescence drives age-attenuated
induction of pituitary tumours in mouse models of
paediatric craniopharyngioma
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Senescent cells may promote tumour progression through the activation of a senescence-
associated secretory phenotype (SASP), whether these cells are capable of initiating
tumourigenesis in vivo is not known. Expression of oncogenic β-catenin in Sox2+ young adult
pituitary stem cells leads to formation of clusters of stem cells and induction of tumours
resembling human adamantinomatous craniopharyngioma (ACP), derived from Sox2− cells
in a paracrine manner. Here, we uncover the mechanisms underlying this paracrine
tumourigenesis. We show that expression of oncogenic β-catenin in Hesx1+ embryonic
precursors also results in stem cell clusters and paracrine tumours. We reveal that human
and mouse clusters are analogous and share a common signature of senescence and SASP.
Finally, we show that mice with reduced senescence and SASP responses exhibit decreased
tumour-inducing potential. Together, we provide evidence that senescence and a stem cell-
associated SASP drive cell transformation and tumour initiation in vivo in an age-dependent
fashion.
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Cellular senescence deﬁnes a state of stable and long-termloss of proliferative capacity, but with retention of normalmetabolic activity and viability1. The activation of the
senescence programme acts as a potent tumour suppression
mechanism through the activation of the p53 pathway and
expression of cell cycle inhibitors (e.g. p21 (CDKN1A) and p16
(CDKN2A))2, 3. The mitogenic stimuli caused by the expression
of several oncogenic proteins, including mutant β-catenin,
BRAFV600E or KRASG12D, trigger DNA replication stress leading
to DNA damage, activation of a DNA damage response (DDR)
and the induction of senescence (named oncogene-induced
senescence, OIS)4, 5. As a result, senescent cells activate a mole-
cular programme characterised by the expression and secretion of
a multitude of growth factors, matrix proteases and pro-
inﬂammatory proteins collectively referred to as the senescence-
associated secretory phenotype (SASP)6. The composition and
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Fig. 1 Tumours in the Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice form non-cell autonomously after a latency period. a Brightﬁeld and epiﬂuorescence
images of 18.5 dpc pituitaries. Note that most of the anterior lobe (al), but not the posterior (pl), is ﬂuorescent in both the Hesx1Cre/+;R26YFP/+ control and
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ pituitaries. The mutant pre-tumoural pituitary is enlarged relative to controls. Scale bar: 1 mm. b Brightﬁeld and
epiﬂuorescence pictures of a pre-tumoural pituitary and tumours in Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ mutant mice at 5, 20 and 35 weeks of age. Most of
the tumour cells are not ﬂuorescent and the YFP+ population (white arrow) is displaced to the periphery of the growing tumour mass (white asterisks).
Scale bar: 5 mm. c Histological characterisation of pre-tumoural pituitaries and developing tumours from 18.5 dpc to 35 weeks postnatally. At 18.5 dpc,
most of the embryonic pituitary is comprised of YFP+ cells (revealed with anti-GFP immunostaining), but there are islands of YFP− cells (DAPI+ areas).
Abundant Ki67+ cells are distributed throughout the pituitary at this stage. At 5 weeks of age, the pre-tumoural pituitary remains mostly quiescent with
very few Ki67+ cells. Note the presence of a dorsal region resembling the normal pituitary tissue of the anterior lobe (al) and a ventral part where YFP− and
YFP+ cells are intermingled. The boundary between dorsal and ventral regions is indicated with a dashed line. At 20 weeks, the YFP− population contains
abundant Ki67+ cells and has expanded dramatically (white asterisks) displacing the mostly quiescent YFP+ cells to the periphery. Around 35 weeks,
mutant mice reach a humane end-point and tumours are mostly YFP− (asterisk). Note that some YFP+ cells are observed in the periphery (white arrow).
Immunohistochemistry against synaptophysin shows that whilst the anterior lobe cells (al) are positive, tumours do not express this endocrine marker
(black asterisk). Immunostaining against β-catenin showing the presence of cell groups (clusters, white arrows) with nucleo-cytoplasmic accumulation of
β-catenin mostly at 18.5 dpc and 5 weeks of age. Subsequently, most of the tumour cells accumulate β-catenin (white asterisk). Results are representative
of experiments conducted in at least three different mice for each stage. Scale bars: 100 μm
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intensity of the SASP response can be affected by factors such as
the senescence-inducing mechanism, cell type and time passed
since senescence initiation, suggesting that the SASP is not a
singular state7–10. The activation of the SASP requires a persistent
DDR and is mediated by the NF-κB and C/EBPβ pathways11.
SASP-associated cytokines, IL-6 and IL-8, reinforce the senescence
growth arrest, at least in some senescent cells12, 13, which is
beneﬁcial in cancer suppression. However, the paracrine activities
of senescent cells through SASP activation can also promote
tumourigenesis. Prominent or persistent SASP activation has been
shown to: (1) disrupt cell–cell adhesion and induce epithelial-to-
mesenchymal transition and invasiveness14, 15; (2) cause local
inﬂammation12, 16; (3) modify tissue architecture17, 18; (4) facil-
itate development of hepatic cancer after carcinogen exposure19,
20; (5) stimulate proliferation of nearby pre- and malignant cells
both in vitro21 and in vivo when co-injected with senescent cells in
xenograft mouse models17, 18, 22 and (6) favour the emergence of
tumour-initiating cells in cell culture models23–26. This bulk of
evidence demonstrates a pro-tumourigenic role for the SASP, but
whether the SASP can induce cell transformation and tumour
initiation of non-tumorigenic cells in vivo remain less clear.
We have previously shown that the expression of a degradation-
resistant form of β-catenin in Rathke’s pouch, the embryonic
primordium of the anterior pituitary gland (Hesx1Cre/+;
Ctnnb1lox(ex3)/+ mice)27, or in Sox2+ adult pituitary stem cells
(Sox2CreERT2/+; Ctnnb1lox(ex3)/+ mice)28 leads to the formation of
tumours that resemble human adamantinomatous craniophar-
yngioma (ACP). Interestingly, targeting expression of this mutant
β-catenin to cell-lineage progenitors or differentiated cells in the
developing pituitary is not tumourigenic, suggesting that the
oncogenic effect requires an undifferentiated stem/cell pre-
cursor27. ACPs are clinically aggressive tumours associated with
high morbidity and signiﬁcant premature mortality29. Most
human ACPs carry mutations in β-catenin leading to the over-
activation of the WNT/β-catenin pathway30–33. In agreement with
this ﬁnding, cells showing nucleo-cytoplasmic accumulation of β-
catenin and activation of the WNT pathway are present in mouse
and human tumours, commonly grouped in whorl-like structures,
named ‘cell clusters’, near the invasive front29. These cell clusters
are not found in any other type of pituitary tumours34, express
stem cell markers27, 35 and have been proposed to play a critical
role in controlling the inﬁltrative behaviour of surrounding
tumour cells36.
Although murine clusters derive from mutant Sox2+; S100B+
adult pituitary stem cells expressing oncogenic β-catenin28, this
population is not the cell-of-origin of the tumours, suggesting a
non-cell autonomous role during tumourigenesis. Currently, the
molecular and cellular mechanisms underlying the pro-
tumorigenic role of this peculiar cell population remain to be
discovered. In this study, we demonstrate through molecular and
genetics approaches that murine and human clusters are func-
tionally equivalent structures, which show a molecular signature
of cellular senescence and a SASP. Our results indicate that
tumour induction only occurs in the presence of robust SASP
activation, therefore providing evidence for a role of senescence
and SASP in tumour initiation in vivo.
Results
Pituitary embryonic precursors can induce paracrine tumours.
We previously showed that the expression of oncogenic β-catenin
in Sox2+ pituitary stem cells in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;
R26YFP/+ mice at 4–6 weeks of age results in the formation of
pituitary tumours in a non-cell autonomous manner28. We
sought to investigate whether a similar mechanism may underlie
the development of pituitary tumours in Hesx1Cre/+;Ctnnb1lox
(ex3)/+;R26YFP/+ mice, another model for human ACP, in which
oncogenic β-catenin is expressed in the embryonic pituitary
precursors that normally give rise to all the cell lineages of the
mature pituitary gland, including Sox2+ stem cells27.
The pituitary gland of the Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+
mice at 18.5 dpc was enlarged in comparison with the Hesx1Cre/+;
R26YFP/+ controls, but did not develop tumours at this stage and
will be hereafter referred to as a ‘pre-tumoural’ pituitary (Fig. 1a).
The vast majority of the cells in the developing anterior pituitary
were YFP+ with abundant Ki67 expression, as expected at this
developmental stage (Fig. 1c). After a variable latency period of
several weeks (median age of 17.7 weeks, range 8.3–35.3 weeks37),
the YFP+ population was progressively replaced by actively
proliferating YFP−;Ki67+ cells (Fig. 1b, c). Eventually, in fully
developed tumours (i.e. when mice reached the humane end-
point), none or only scarce YFP+ cells could be observed in the
periphery of the majority of the tumours (8 out of 11), which
were comprised mostly of YFP− cells. Notably, Ki67 expression
was mostly observed in YFP− cells at this point (Fig. 1c).
Similar results were obtained from Hesx1Cre/+;Ctnnb1lox(ex3)/+;
R26mTmG/+ mice, in which 4 out of 5 tumours contained large
tdTomato+ areas, indicating that tumour cells were not
recombined (Supplementary Fig. 1). β-catenin-accumulating
cell clusters were evident at pre-tumoural stages and as expected
were YFP+ (Fig. 1c) and Ki67−27. As tumours developed,
β-catenin expression was elevated in YFP− cells and clusters
were no longer identiﬁable (e.g. after 20 weeks) (Fig. 1c).
Additionally, YFP− cells were synaptophysin-, suggesting that
these are not neuroendocrine cells (Fig. 1c).
Exome sequencing of 15 murine tumours revealed the presence
of a total of 272 mutations (average 18.13 mutations per tumour;
Supplementary Data 2) of which 131 were in coding regions
(average 8.73 mutations per tumour; Supplementary Data 2). Of a
selection of 14 of these 131 mutations, we validated 12 by Sanger
sequencing (i.e. they were identiﬁed in the same DNA used for
exome sequencing) (Supplementary Data 2). Only three genes
were recurrently mutated in either two or three separate tumours
and no recurrent mutations were found present in all 15 tumours
(Supplementary Data 2). A low mutational burden with few
recurrent mutated genes, other than CTNNB1, has been described
Table 1 Recurrently mutated genes in mouse and human ACP
Human ACP Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours
Gene cDNA change Protein change Variant classiﬁcation Gene cDNA change Protein change Variant classiﬁcation
ASCC2 c.1861G>A p.D621N Missense Ascc2 c.1016+10G>A NA Splice region
DNAJC3 c.1243C>T p.R415* Nonsense Dnajc3 c.1381G>T p.G461* Nonsense
KIF1C c.2087G>A p.R696Q Missense Kif1c c.474G>T p.L158F Missense
PKD1L1 c.3862C>T p.R1288C Missense Pkd1l1 c.55G>T p.W19C Missense
TGFBI c.1286C>T p.A429V Missense Tgfbi c.662A>C p.D221A Missense
*Nonsense mutation
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in human ACP33. To determine if these changes are representa-
tive of the mutagenic process occurring in human ACP, we
carried out comparisons with the published exome sequence
results of 12 human ACPs33. This revealed 12 genes carrying
mutations in both human and mouse tumours, but none of these
mutations were identical between species (Supplementary Data 2).
Five of these 12 mutated genes harboured non-silent/intronic
mutations in both species (Table 1). The functional signiﬁcance of
these mutations is currently unknown.
Together, these ﬁndings demonstrate that the activation of
oncogenic β-catenin in Hesx1+ pituitary embryonic precursors
leads to cell transformation and formation of somatic mutations-
bearing tumours, which are mostly not derived from the Hesx1
cell lineage. Additionally, our time course analysis reveals that
tumour initiation requires a latency period of several weeks and is
preceded by formation of β-catenin-accumulating cell clusters in
the pre-tumoural pituitary.
ACP clusters contain senescent cells with an activated SASP.
The observation that cluster cells do not divide led us to hypothesise
that the expression of mutant β-catenin may result in oncogene-
induced senescence. We analysed the expression of a panel of
senescence-associated markers by immunostaining in mutant
mouse embryos at 18.5 dpc and 23 different human ACP samples
to assess whether hallmark senescence features were present in
cluster cells including: (i) cell cycle arrest; (ii) DNA damage and
activation of a DDR and (iii) increased lysosomal content1, 38.
Cluster cells were negative for the mitotic marker phospho-
histone H3 and did not incorporate 5-ethynyl-2′-deoxyuridine
(EdU), a speciﬁc indicator of S phase. Cell death was not detected
by caspase 3 immunostaining (Supplementary Fig. 2). Human β-
catenin-accumulating cluster cells are also negative for Ki67 and
caspase 336, 39. Murine and human clusters exhibited marked
expression of p53 (TP53), p21 (CDKN1A) and p16 (CDKN2A),
all crucial effectors of cell cycle arrest38 (Fig. 2a, b; Supplementary
Fig. 3a, b). Cluster cells in mouse and human ACP expressed γ-
H2AX, suggesting the presence of DNA damage40; as well as
phospho-DNA-PKcs, PARP1 and phospho-ATM, therefore
revealing DDR activation41, 42 (Fig. 2a, b; Supplementary Fig. 3c,
d). The senescence-associated β-galactosidase (SA-βgal) staining
is a classical assay to identify senescent cells by detecting the
presence of the lysosomal enzyme β-D-galactosidase43, the
product of the GLB1 gene44. SA-βgal staining on Hesx1Cre/+;
Ctnnb1lox(ex3)/+ mutant pituitaries (Supplementary Fig. 3e) and
double immunoﬂuorescence for β-catenin and GLB1 revealed the
expression of GLB1 in the cell clusters in both mouse and human
ACP (Fig. 2a, b). LAMP1, LAMP2 and lysozyme C expression
were also upregulated in cluster cells, suggesting the enlargement
of the lysosomal compartment, another feature of senescent cells
(Supplementary Fig. 3f, g)44, 45.
The activation of the NF-κB pathway is required for survival of
senescent cells and activation of SASP11. As a read out of an
activated NF-κB pathway, we assessed the presence of phospho-
IκBα, as phosphorylation at Ser32 and Ser36 of IκBα is followed
by proteasome-mediated degradation and pathway activation46.
Mouse and human clusters expressed high levels of p-IκBα
(Fig. 3a, b). RELA/p65 and NEMO, two crucial components of
the NF-κB pathway, were broadly expressed throughout the
tissue, including cluster cells of both species (Fig. 3a, b). Finally,
to determine if senescence and the SASP response are initiated
together with cluster formation and prior to any tumour
initiation, we turned to the early stages of mutant pituitary
development in the embryonic mouse model. Analysis of
Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryonic pituitaries from 10.5 to
18.5 dpc revealed a dynamic response for the different aspects of
senescence in the cluster cells. Proliferation in β-catenin-
accumulating cluster cells, as assessed by Ki67 and EdU
incorporation, was higher at 10.5 dpc than 18.5 dpc, whilst
expression of the cell cycle inhibitors p16 and p21 was detected
in the majority of the cluster cells from 10.5 dpc (Supplementary
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Fig. 2 β-catenin-accumulating cluster cells in mouse and human ACP express senescence markers. Double immunostaining on histological sections of
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pre-tumoural pituitaries at 18.5 dpc (a) and human ACP tumours (b). Note that cluster cells (arrows) express lysosomal
enzymes such as GLB1, encoding senescence-associated β-galactosidase, the cell cycle regulators p21 and p53, as well as the DNA damage and DNA
damage response markers gamma histone 2AX and phospho-DNA-PKcs, respectively. Results are representative from experiments conducted in six to
eight mice and 23 human ACP tumours. Normal brain was used as negative control. Scale bars: a 50 μm; b 100 μm
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Fig. 4a, b). The DDR and NF-κB pathways became active by
10.5–12.5 dpc (Supplementary Fig. 4c), whereas expansion of the
lysosomal compartment occurred later in development around
16.5–18.5 dpc (Supplementary Fig. 4a, b, d). Therefore, the
senescence/SASP response is initiated at early stages of develop-
ment, soon after the emergence of tumours.
SASP activation results in alterations in normal tissue
architecture and increased angiogenesis6, therefore, we sought
to analyse the tumour microenvironment in Hesx1Cre/+;
Ctnnb1lox(ex3)/+ pituitaries at 18.5 dpc. In controls, immunostain-
ing against endomucin (EMCN), a sialoglycoprotein routinely
used as a marker of endothelial cells47, revealed the presence of
cells with a thin and elongated morphology surrounding the
lumen of blood vessels in the anterior lobe of the control
pituitaries (Fig. 4a). In contrast, Hesx1Cre/+;Ctnnb1lox(ex3)/+
pituitaries displayed a drastic expansion of the EMCN+
population, which formed large and dense groups of cells without
the presence of a lumen (Fig. 4a). Double immunostaining against
YFP and EMCN in the Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+
pituitaries revealed mutually exclusive staining with the EMCN
cells occupying almost entirely the YFP− areas (Fig. 4b).
Expression of extra-cellular matrix proteins such as ﬁbronectin
and laminin was altered in the Hesx1Cre/+;Ctnnb1lox(ex3)/+
pre-tumoural pituitaries when compared with controls (Fig. 4a).
Interestingly, EMCN+ cells frequently formed ring-like structures
surrounding YFP+ cells, which resembled the β-catenin-
accumulating clusters. Triple immunostaining against SOX9,
β-catenin and EMCN conﬁrmed that the cells directly surround-
ing the clusters are SOX9+;EMCN+ (Fig. 4c). Together, these
results suggest that cluster cells activate a senescence and SASP
programme leading to changes in the cellular microenvironment
of the pre-tumoural pituitary.
ACP clusters show a senescence/SASP molecular signature. The
expression of oncogenic β-catenin in Sox2+ pituitary stem cells in
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice at 4–6 weeks of age
results in cluster formation and induction of paracrine tumours28.
However, the molecular signature of the cluster cells in
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice has not yet been
revealed. To this end, we ﬁrst induced Sox2CreERT2/+;
Ctnnb1lox(ex3)/+;R26YFP/+ mice at 4 weeks of age by tamoxifen
administration and analysed the pituitaries 4 weeks later.
Following dissociation into single-cell suspensions, YFP+ and
YFP− cells were isolated by ﬂow sorting and subjected to
qRT-PCR analysis. This revealed a gene expression proﬁle
consistent with the presence of β-catenin-accumulating cluster
cells in the YFP+ population (Supplementary Fig. 5b).
Next we sought to reveal the molecular signature of cluster cells
relative to normal Sox2+ cells not expressing oncogenic β-catenin.
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+mutant and Sox2CreERT2/+;
R26YFP/+ control mice were tamoxifen induced at 4 weeks of age
and pituitaries dissociated and subjected to RNA sequencing
4 weeks later. The expression data for all of the 27,179 genes are
included in Supplementary Data 3 and the demonstration of a
successful experimental approach in Supplementary Fig. 5a. Of
note, differential expression studies demonstrated the upregulation
of several members of the hedgehog (HH), ﬁbroblast growth factor
(FGF), bone morphogenetic protein (BMP), wingless-related
integration site (WNT) and transforming growth factor
β (TGFβ) families as well as CXC chemokines and interleukins
(Supplementary Data 3). These results support the notion that
cluster cells are signalling hubs in the pre-tumoural pituitary.
To assess in an unbiased manner whether cluster cells in
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+
(previously characterised48) mice activate senescence and a SASP,
we speciﬁcally compared the expression proﬁles of the murine
clusters with established molecular signatures for OIS and SASP
obtained from human IMR90 ER:RAS ﬁbroblasts. These cells
express a Steroid Receptor-KRASG12V chimaeric fusion protein
that triggers growth arrest, senescence and SASP13. Gene set
enrichment analysis (GSEA) showed that the gene expression
proﬁles of the clusters in both mouse models were signiﬁcantly
enriched for OIS and SASP genes (Fig. 5a, c). This was further
validated by qRT-PCR (Fig. 5b, d). SASP activation was further
investigated using semi-quantitative ELISA cytokine arrays,
which demonstrated the upregulation of several SASP-related
proteins, such as ICAM1, bFGF, IL1A, IFNG, OPN, IL6, IGFBL6,
MMP3, MMP2, RNAKL1, CXCL1, CXCL11, IL7, TIMP2,
VEGFR1 and CCL11) (Fig. 5e).
To determine whether these ﬁndings were relevant to human
ACP, we assessed the degree of molecular equivalence between
mouse and human ACP clusters. We recently analysed the
molecular signatures of speciﬁc tumour cell compartments in
human ACP including the β-catenin-accumulating cell clusters,
by combining laser-capture microdissection and RNA-
Sequencing (J.R. Apps and J.P. Martinez-Barbera, manuscript
submitted, Array Express accession code: E-MTAB-5266).
Hierarchical clustering analysis revealed the grouping of
Hesx1Cre/+;Ctnnb1lox(ex3)/+, Sox2CreERT2/+;Ctnnb1lox(ex3)/+ and
human clusters, suggesting similar molecular proﬁles (Fig. 5g),
while GSEA conﬁrmed that human clusters also have a molecular
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Fig. 3 Cluster cells show activation of the NFκB pathway. Double immunostaining on histological sections of Hesx1Cre/+;Ctnnb1lox(ex3)/+ pre-tumoural pituitaries
at 18.5 dpc (a) and human ACP tumours (b). Phospho-IκBα, a readout of activated NFκB pathway, as well as RELA and NEMO, two components of this
pathway, are expressed in cluster cells (white arrows). Results are representative of experiments conducted in four to six mice. Scale bar: a 50 μm; b 100 μm
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signature of senescence and SASP (Fig. 5f). Moreover, GSEA
analysis of Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Sox2CreERT2/+;
Ctnnb1lox(ex3)/+ cluster gene expression proﬁles showed a
signiﬁcant enrichment for the top 100 and 500 most upregulated
genes in human clusters (Fig. 5h, i). Together, these analyses
support that human and mouse clusters are equivalent structures,
sharing a common signature of senescence and SASP.
Aged Sox2+ stem cells show reduced tumour-inducing poten-
tial. We sought to determine whether the age at which
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice were targeted to express the
oncogenic β-catenin may have an effect on paracrine
tumourigenesis.
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mutant mice were tamoxifen
induced at either 1 month, when pituitary stem cells are still
actively supporting organ growth, or at 6–9 months of age when
contribution from Sox2+ stem cells to homeostasis is low.
Pituitaries were analysed at 3 months post induction and assessed
for tumour formation. Histological analysis revealed that 15/15
mice that were induced at 1 month of age developed pituitary
tumours with a total of 48 individual lesions (average 2–4
tumours per pituitary). However, only 3 out of 17 mice induced at
6–9 months of age developed pituitary tumours with only ﬁve
individual lesions observed (p< 0.0001; Table 2).
We decided to explore whether the reduced tumour burden in
older Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice may be related to an
attenuated senescence and SASP response in the β-catenin-
accumulating clusters. To achieve this, YFP+ cells were isolated
by ﬂow cytometry from Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+
mutant and Sox2CreERT2/+;R26YFP/+ control mice that were
induced at either one month or 6–9 months of age (Fig. 6a).
Relative to age-matched control YFP+ cells, YFP+ cells from
older mice activated the WNT pathway and a senescence/SASP
programme (Fig. 6d). Although both age groups contained
Ki67−/p21+ β-catenin-accumulating clusters (Fig. 6b), the
average number of cells in the clusters of young-induced
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mutant mice was 3.16
± 1.57 vs. 1.95± 1.12 in older-induced animals, afﬁrming that
clusters from older mice were smaller in size (p< 0.0001,
Student’s t test; 57 clusters counted in three young Sox2CreERT2/
+;Ctnnb1lox(ex3)/+;R26YFP/+ pituitaries and 94 clusters counted in
six older Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ pituitaries). In
addition, increased Ki67 index was observed only in non-cluster
cells in the younger, but not in the older Sox2CreERT2/+;Ctnnb1lox
(ex3)/+;R26YFP/+ pituitaries, suggesting that Sox2+ cluster cells
from younger mice can induce a proliferative response in
surrounding cells (Fig. 6c).
Importantly, comparative analysis between the YFP+ fractions
of Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mutants revealed a
signiﬁcant reduction in the expression of senescence and SASP
factors in mice induced at 6–9 months relative to the one month-
induced mice (Fig. 6e). We also observed an age-dependent
increase in the expression of senescence-associated markers, such
as p16 (Cdkn2a) and p53 (Trp53), in non-mutant Sox2+ cells in
Sox2CreERT2/+;R26YFP/+ control pituitaries, which may underlie
the ameliorated senescence/SASP response of older relative to
younger mutant Sox2+ stem cells (Supplementary Fig. 6).
Together, these analyses demonstrate that expression of onco-
genic β-catenin in Sox2+ stem cells in 6–9 months old mice is less
tumourigenic and leads to weakened senescence and SASP
responses with formation of smaller β-catenin-accumulating
clusters.
Apc-deﬁcient clusters lack tumour-inducing potential. The
data previously described in Hesx1Cre/+;Ctnnb1lox(ex3)/+ and
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice are compatible with a model
whereby senescent cells in the β-catenin-accumulating clusters of
the pre-tumoural pituitary may initiate tumourigenesis by acti-
vating a robust SASP programme. Therefore, we sought to
explore whether the reduction or ablation of senescent cells may
prevent or delay tumourigenesis.
The senolytic compounds ABT-263 and ABT-737 have
been shown to selectively ablate senescent cells in vitro and
in vivo49, 50. In agreement with these ﬁndings, ex vivo culture of
18.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ pre-tumoural pituitaries in
the presence of ABT-263 and ABT-737 revealed a reduction in
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the average size of the clusters, but this did not reach signiﬁcance
(number of cells per cluster: vehicle 2.46± 1.26, 41 clusters
counted from three pituitaries; ABT-263, 1.4± 0.49, p = 0.47, 40
clusters counted from four pituitaries; ABT-737, 1.8± 0.62, p =
0.70, 38 clusters counted from three pituitaries; Student’s t test)
(Supplementary Fig. 7c, d). In contrast, treatment of IMR90 ER:
RAS senescent ﬁbroblasts with these two senolytic agents
signiﬁcantly increased cell death relative to control non-
senescent cells (Supplementary Fig. 7a, b). The distinct target
cell type (i.e. epithelial cluster cell rather than ﬁbroblast) may
confer a resistance to these drugs and, additionally, drug delivery
and dose may require further optimisation. The drugs target
genes Bcl2, Bcl-xl and Bcl-w are all expressed in the cluster cells,
but not upregulated.
Since chemical ablation of senescent cells was not strong
enough to reduce signiﬁcantly the size of the clusters, we sought
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to explore whether a genetic approach may impair the senescent/
SASP response more robustly. It has been shown that the strength
of the senescence/SASP response depends on the oncogenic hit;
e.g. the activation of the mitogen-activated protein kinase
(MAPK) pathway by BRAFV600E is a more potent senescence
inducer than KRASG12V 51. We reasoned that the deletion of
tumour suppressor Apc in Hesx1Cre/+;Apcﬂ/ﬂ mice would lead to
the activation of the WNT pathway in embryonic precursors and
the accumulation of wild-type β-catenin rather than its
degradation-resistant form, which is encoded by the oncogenic
Ctnnb1 locus in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice. We expected
wild-type β-catenin to be a weaker senescence inducer than
oncogenic β-catenin, resulting in reduced senescence/SASP
activation.
Hesx1Cre/+;Apcﬂ/ﬂ mice were born at the expected Mendelian
ratios, were normal and fertile with proper speciﬁcation of
pituitary endocrine lineages (Supplementary Data 4; Supplemen-
tary Fig. 8a). Although slight pituitary hyperplasia was consistently
observed, no pituitary tumours ever formed in Hesx1Cre/+;Apcﬂ/ﬂ
mice (n = 61), even when followed until 18 months of age (n = 17)
(Fig. 7a; Supplementary Fig. 8a). Immunostaining studies revealed
the presence of nucleo-cytoplasmic β-catenin-accumulating
clusters in Hesx1Cre/+;Apcﬂ/ﬂ embryos. These clusters resembled
their oncogenic β-catenin counterparts in many ways, such as in
the expression of SOX2, but not SOX9, and WNT pathway
activation as evidenced by the over-expression of the WNT-target
gene Axin2 (Fig. 7d; Supplementary Fig. 8b). Additionally, cluster
cells in the Apc mutant pituitary were negative for Ki67,
phospho-Histone H3, or Caspase 3 and expressed the cell cycle
inhibitors p21 and p16 (Fig. 7b; Supplementary Fig. 8c, d).
Moreover, these clusters were strongly positive for DDR and
NF-κB activation markers such as phospho-DNA-PKcs, PARP-1
and phospho-IκBα, indicative of the activation of a senescence
programme (Fig. 7b; Supplementary Fig. 8d). Despite the
similarities in gene expression, the average cluster size at 18.5
dpc in Hesx1Cre/+;Apcﬂ/ﬂ pituitaries was 1.97± 1.36 cells,
rather than 5.89± 0.33 in Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos
(p< 0.0001, Student’s t test; 126 clusters counted for Hesx1Cre/+;
Ctnnb1lox(ex3)/+ and 108 clusters counted for Hesx1Cre/+;Apcﬂ/ﬂ in
three different pituitaries).
qRT-PCR analysis comparing Hesx1Cre/+;Apcﬂ/ﬂ to Apcﬂ/+
control pituitaries revealed no signiﬁcant differences in the
expression levels of several senescence and SASP factors including
Cdkn1a, Cdkn2a, Shh, Bmp4, Il1a, Il1b, Il6, Cxcl1 and Tgfb1
(Supplementary Fig. 8e). However when comparing expression
levels of senescence/SASP factors relative to Hesx1Cre/+;Ctnnb1lox
(ex3)/+ pituitaries, these were reduced in Hesx1Cre/+;
Apcﬂ/ﬂ mutants (Fig. 7c), suggesting an overall reduction of the
senescence/SASP response upon Apc deletion and in line with the
formation of smaller clusters. In situ hybridisation previously
conﬁrmed the upregulation of Axin2, Bmp4, Fgf3 and Shh in
Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters27. In contrast, despite
Hesx1Cre/+;Apcﬂ/ﬂ clusters expressing Axin2 and demonstrating
WNT pathway activation, the expression of Bmp4, Fgf3 and Shh
expression was not detectable (Fig. 7d). Moreover, the abundant
SOX9+;EMCN+ cells surrounding the clusters in the Hesx1Cre/+;
Ctnnb1lox(ex3)/+ pituitaries (Fig. 4c) were not apparent in
Hesx1Cre/+;Apcﬂ/ﬂ mutant glands (Fig. 7e), and overall quantiﬁca-
tion of the area covered by endomucin positive cells revealed
values comparable to control littermates (Fig. 7f). In a Hesx1Cre/+;
Apcﬂ/ﬂ pituitary where a larger cluster was identiﬁed, accumula-
tion of EMCN+ cells was observed around it (Supplementary
Fig. 8f), suggesting that a threshold of SASP factors may be
needed to elicit the changes in tissue architecture. Finally, no
tumours developed in Sox2CreERT2/+;Apcﬂ/ﬂ mice induced from 4
to 8 weeks of age in a follow up of up to a year (n = 7 mice).
Together, these studies demonstrate that Apc deletion in pituitary
embryonic precursors/stem cells leads to reduced senescence/
SASP response and is not tumorigenic.
Discussion
In this paper, we show that the expression of oncogenic β-catenin
and activation of the WNT pathway in Hesx1+ embryonic
pituitary precursors or Sox2+ pituitary stem cells in young mice
results in the activation of a robust SASP in targeted cells and the
subsequent paracrine formation of tumours. These mouse
tumours carry a low burden of somatic mutations that are mostly
non-recurrent, which overlap with human ACP. To our knowl-
edge, this is the ﬁrst time that SASP activation is associated with
non-cell autonomous cell transformation (i.e. induction of
somatic mutations) and tumour initiation in an in vivo murine
model of a human tumour. Of note, we refer to cell transfor-
mation to indicate the occurrence of somatic mutations not
present in the germline and the acquisition of a proliferative
advantage of the tumour relative to the non-tumour cells. How-
ever, mouse and human ACP do not harbour mutations in critical
cancer genes (e.g. p53, p16, Myc, Braf, Egfr among others) sug-
gesting that these tumours are not fully transformed. This is not
surprising as human ACP is a benign tumour that very rarely
progresses into a malignancy. A summary of the main ﬁndings of
this study is shown in Fig. 8.
In the embryonic mouse ACP model, tumour progression does
not start immediately after birth, but only after a latency period in
Fig. 5 Mouse and human β-catenin-accumulating clusters share a common signature of senescence and SASP. a–d Gene set enrichment analysis (GSEA)
(a, c) revealing that clusters from both mouse models, the Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Sox2CrERT2e/+;Ctnnb1lox(ex3)/+;R26YFP/+, show a molecular
signature of oncogene-induced senescence (OIS) and senescence-associated secretory phenotype (SASP). qRT-PCR analysis showing the upregulation of
several senescence and SASP factors in both mouse models (b, d). Bars in b and d represent the mean, and error bars represent standard error of the
mean (SEM) of three biological replicates. *p< 0.05, **p< 0.01, ***p< 0.001, Student’s t test. e Several cytokines are upregulated in the Hesx1Cre/+;
Ctnnb1lox(ex3)/+ mutant relative to the Hesx1+/+;Ctnnb1lox(ex3)/+ control pituitaries as measured in a mouse cytokine antibody array. f Gene set enrichment
analysis (GSEA) demonstrating that laser-capture micro-dissected human clusters show a molecular signature of oncogene-induced senescence (OIS) and
senescence-associated secretory phenotype (SASP). g Hierarchical clustering analysis of RNA-data sets from cluster and non-cluster cell populations
indicating coherent grouping between speciﬁc cell compartments. h, i GSEA of the top 100 or 500 most upregulated genes in human clusters and the
whole transcriptome of mouse clusters from both models demonstrating a common molecular signature
Table 2 Reduced tumour-inducing potential in older vs.
young Sox2+ pituitary stem cells
Sox2CreERT2/+; Ctnnb1lox(ex3)/+; R26YFP/+
Age at tamoxifen
induction
Tumour incidencea Number of mice
1 month 15 (48 lesions) 15
6–9 months* 3 (5 lesions) 17
*Unpaired t-test showed a statistically signiﬁcant difference in tumour formation between age
groups (p=< 0.0001)
a Tumour incidence was assessed histologically at 3 months post-tamoxifen induction
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which the pre-tumoural pituitary contains senescent clusters with
an activated SASP. This non-linear growth dynamics have
recently been characterised by magnetic resonance imaging37.
The pre-tumoural pituitary also shows abnormal tissue archi-
tecture and overall slow cell proliferation. However, once rapidly
dividing tumour cells appear, the clusters and most of the normal
pituitary tissue are displaced. This growth pattern is compatible
with the clusters’ activities being required to initiate a process
eventually leading to tumour initiation (hit-and-run model),
rather than promoting tumour progression, which may be self-
sustaining. Recently, it has been shown that senescence cells
through SASP can induce dedifferentiation and stem cell marker
expression52. Transcriptomics failed to reveal the expression of
Hesx1, but stem cell markers such as SOX9, Klf2, Klf4 and Cmyc
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Fig. 6 Aged Sox2+ stem cells generate β-catenin-accumulating cell clusters with reduced senescence and SASP responses. a Schematic diagram of the
experimental designs. Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ and Sox2CreERT2/+;R26YFP/+ mice were tamoxifen induced at either 1 or 6 month of age and
the anterior pituitary collected 4 weeks post induction and processed for histological and molecular analysis of YFP+ cells isolated by FACS (n= 8 mice per
group). b Double immunostaining on histological sections of Sox2CreERT2/+; Ctnnb1lox(ex3)/+; R26YFP/+ pituitaries revealing the presence of β-catenin-
accumulating cell clusters positive for p21, but not for Ki67. Scale bar: 100 µm. c Quantitative analysis showing a signiﬁcant higher Ki67 proliferation index
in non-cluster cells in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ tumoural relative to Sox2CreERT2/+;R26YFP/+ control pituitaries in tamoxifen-induced mice at
1 month (black asterisk), but not at 6 months. Increased proliferation index is also observed in non-cluster cells in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+
pituitaries of mice induced at 1 month relative to those induced at 6 months (red asterisk). d qRT-PCR analysis showing the upregulation of the WNT
pathway target genes Axin2 and Lef1, as well as of several senescence and SASP factors in the Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mutant pituitaries
relative to the Sox2CreERT2/+; R26YFP/+ controls. e qRT analysis showing the relative expression of several senescence and SASP factors in Sox2CreERT2/+;
Ctnnb1lox(ex3)/+;R26YFP/+ mice tamoxifen induced at either 1 (young) or 6 (older) months of age. The expression of several senescent and SASP factors is
signiﬁcantly reduced in the older compared with the young mice. Bars in c, d and e represent the mean, and error bars represent standard error of the mean
(SEM) of three biological replicates. *p< 0.05, **p< 0.01, ***p< 0.001, Student’s t test
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Fig. 7 Deletion of the tumour suppressor Apc results in β-catenin-accumulating senescent clusters with reduced SASP. a Brightﬁeld and
haematoxylin–eosin pictures of wild-type and Hesx1Cre/+;Apcﬂ/ﬂ pituitaries, and Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary tumours. Note that the Apc-deﬁcient
pituitary is enlarged but no tumours are apparent and it is histologically normal. The age of the mice is indicated in weeks. Scale bar: 1 mm. b Double
immunostaining revealing the expression of p21, phospho-IκBα and phospho-DNA-PKcs in the β-catenin-accumulating clusters, indicating cell cycle
inhibition and activation of the NFκB and DNA damage response pathways, in both Hesx1Cre/+;Apcﬂ/ﬂ and Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries at 18.5 dpc.
Note that the clusters are smaller in the Hesx1Cre/+;Apcﬂ/ﬂ compared with the Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. Scale bar: 50 μm. c qRT-PCR analysis
showing the relative expression of several genes in Hesx1Cre/+;Apcﬂ/ﬂ relative to Hesx1Cre/+; Ctnnb1lox(ex3)/+ pituitaries at 18.5 dpc. The expression of the
WNT pathway targets Axin2 and Lef1 are similar between the two genotypes, but several senescence and SASP factors show reduced expression levels in
the Hesx1Cre/+;Apcﬂ/ﬂ compared with the Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. Bars represent the mean, and error bars represent standard error of the
mean (SEM) of three biological replicates. *p< 0.05, **p< 0.01, Student’s t test. d In situ hybridisation on histological sections of embryos at 14.5 dpc
showing the expression of Axin2 in small cell clusters and very reduced or absent detection of Bmp4, Fgf3 and Shh in the Apc-deﬁcient pituitaries. Scale bar:
100 μm. e Triple immunostaining revealing the expression of β-catenin, SOX9 and EMCN. Note that the large areas of EMCN+;SOX9+ cells surrounding the
β-catenin-accumulating clusters are not present in the Hesx1Cre/+;Apcﬂ/ﬂ pituitaries. Scale bar: 50 μm. f Quantiﬁcation of the EMCN+ areas demonstrating
that wild-type and Apc-deﬁcient pituitaries show similar levels, which are signiﬁcantly increased in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. Bars represent
the mean, and error bars represent standard error of the mean (SEM) of three biological replicates. ***p< 0.001, one-way ANOVA. All results are
representative of at least three biological replicates
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were upregulated in mouse tumours (J.R. Apps and J.P. Martinez-
Barbera, manuscript submitted), sometimes in close proximity to
the senescent cluster cells (i.e. SOX9; Fig. 4c)27. Immunostaining
against SOX2 showed lack of expression of this stem cell marker
in the murine tumours (Supplementary Fig. 9). In human ACP,
the expression of stem cell markers (e.g. SOX2, SOX9, KLF4 and
OCT4) has been found to be upregulated53. These results are
compatible with a potential role of the senescent cluster cells in
the promotion of reprogramming in vivo, a hypothesis that
merits further research.
Elegant genetic experiments have shown that senescence is
important to prevent tumourigenesis in mouse models of pitui-
tary adenoma54. In agreement with this notion, our data suggest
that senescence has an early cell-autonomous function that pre-
vents the expansion of cluster cells harbouring oncogenic β-
catenin. However, we reveal an additional non-cell autonomous
role of senescent cells, mediated by the persistent activation of
SASP resulting in paracrine cell transformation and tumour-
igenesis. Ablation of the senescent cluster cells at speciﬁc time
points using chemical or genetic approaches will further help
dissect their role in tumourigenesis. In particular, it will help
determine when and for how long their activities are required for
tumour initiation and/or maintenance.
We also reveal molecular similarities between the mouse and
human clusters, which provide insights into the pathogenesis of
human ACP. In contrast to the mouse tumours, the β-catenin-
accumulating clusters are present in fully developed human ACP
and tend to be located at the tips of ﬁnger-like epithelial pro-
trusions that invade the brain36, 37. Analysis of a human ACP
xenograft model suggest that the activities of the clusters are
important in orchestrating cell migration and tumour invasion36.
We show that β-catenin clusters undergo senescence and initiate
SASP during embryonic pituitary development in the mouse, and
this supports the notion that childhood-onset ACP is a devel-
opmental tumour. This proposition is substantiated by the scru-
tiny of clinical data, which has revealed that paediatric ACP
patients suffer signiﬁcant height deﬁcits around 12 months of age,
many years before ACP diagnosis, suggesting potential growth
hormone deﬁciency55. Of note, somatotrophs, which express
growth hormone, are clearly defective in the Hesx1Cre/+;
Ctnnb1lox(ex3)/+ ACP model by the end of gestation27. Therefore,
clusters may develop embryonically in human patients and be
present in the pituitary gland of the newborn prior to the
appearance of any tumour mass. In fact, foetal ACPs displaying
nucleo-cytoplasmic β-catenin-accumulating cells have recently
been diagnosed in human foetus at 18 weeks56. Additionally, we
show that the SASP response is attenuated with age in Sox2+
pituitary stem cells in older mice, which is in agreement with
ACP being primarily a paediatric tumour29.
Paracrine tumourigenesis has been reported in other tumours
and cancers, but so far not associated with senescence and SASP.
Over-expression of platelet-derived growth factor (PDGF) (also a
SASP factor) in neural precursors in mice and rats is sufﬁcient to
recruit normal neural stem and progenitor cells that acquired
genetic aberrations and become malignant, capable of generating
tumours upon transplantation57–59. Likewise, conditional dele-
tion of Notch1 in mouse skin epidermis60 or activation of β-
catenin in hair follicles stem cells by deleting Ctnnb1 exon 361
leads to over-activation of the WNT/β-catenin pathway and
induction of tumours/growths in a non-cell autonomous manner.
Additionally, the expression of a constitutively active form of
MEK1, activating the ERK MAPK pathway, in mouse epidermis
results in skin polyps, which are mostly formed by cells not
carrying oncogenic MEK162. More strikingly, in a mouse model
for leukaemia the expression oncogenic β-catenin (i.e. Ctnnb1
deletion of exon3) in osteoblast precursors is sufﬁcient to generate
oncogenic hematopoietic stem cells capable of giving rise and
propagating acute myeloid leukaemia63. Whether in these models
the tumour-inducing cells are senescent and have activated SASP
is an important aspect that merits further research. Our results
support the possibility that the activities of the senescent cells
result in changes in the cellular microenvironment driving genetic
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Fig. 8 Schematic summary of the main ﬁndings of this research. a Targeting Sox2+ stem cells from young adults, or Hesx1+ embryonic precursors to
express oncogenic β-catenin, results in formation of senescent cell clusters and a robust SASP. This leads to cell transformation and generation of the cell-
of-origin of the paracrine tumours, thus the tumours are not derived from the mutation-sustaining cells. b In contrast, the expression of oncogenic β-
catenin in Sox2+ stem cells of older mice leads to a reduced tumour incidence or the failure to produce tumours. In addition, upregulation of the WNT
pathway through the deletion of Apc in young adult stem cells or embryonic precursors also fails to induce tumours. In all cases described in b, there is
attenuated senescence and SASP activation
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and possibly, epigenetic changes in neighbouring cells, which may
fuel tumour initiation in some of these neoplasias.
In summary, this study provides evidence for a mechanism by
which embryonic progenitors and postnatal stem cells can con-
tribute to tumourigenesis in a non-cell autonomous manner,
identifying senescence and SASP as mediators of this tumour-
inducing potential. Recent research has demonstrated that clear-
ance of senescent cells, either naturally occurring in aged mice or
diseased related, extends lifespan, improves the physiological
function of several organs and delays tumourigenesis49, 50, 64.
Although the ablation of the cluster cells in the ACP mouse model
was only partial, these results reinforce the idea that cluster cells
are senescent and suggest that senolytic compounds may be of
potential therapeutic interest against human ACP. The develop-
ment of more speciﬁc senolytics capable of targeting a variety of
senescent cells, including pituitary epithelial cells targeted with
oncogenic β-catenin, will be required to further study the potential
anti-tumourigenic effects of senescence ablation in the context of
ACP and other tumours. In addition, further research is required
to identify the pro- and anti-tumourigenic mediators in the SASP,
and the mouse models presented here are suitable tools to dissect
these opposite functions.
Methods
Mice and human samples of ACP. The Ctnnb1lox(ex3)/+, Sox2CreERT2/+, Hesx1Cre/+,
ROSA26ﬂox-stop-YFP/+, Apcﬂox/+ and ROSAmTmG/+ mice have been previously
described28, 48, 65, 66. Sox2CreERT2/+; Ctnnb1lox(ex3)/+; ROSA26ﬂox-stop-YFP/+ and
Sox2CreERT2/+; ROSA26ﬂox-stop-YFP/+mice were induced with a single intra-peritoneal
injection of tamoxifen (Sigma, T5648) at a dose of 0.15 mg per gram of body weight.
All mouse procedures were performed under licence, following UK Home Ofﬁce
Animals (Scientiﬁc Procedures) Act 1986 and local institutional guidelines (UCL
ethical review committee). A humane end-point was chosen to avoid severe adverse
effects and minimise suffering of mice harbouring tumours, according to UK Home
Ofﬁce and local Ethical Committee regulations. Samples of human ACP were
obtained from the Department of Histopathology at Great Ormond Street Hospital
for Children and the CCLG tissue bank with full consent (Research Ethics
Committee application, REC 14 LO 2265).
Flow-activated cell sorting. Anterior pituitaries from age- and sex-matched mice
were dissociated mechanically into single-cell suspensions following incubation in
enzyme mix (0.5% w/v Collagenase type 2 (Lorne Laboratories Ltd.), 0.1× Trypsin
(Gibco) and 50 μg/ml DNaseI (Worthington) with 2.5 μg/ml Fungizone (Gibco) in
Hank’s Balanced Salt Solution (HBSS (Gibco) for 4 h at 37 °C. Cells were then
washed in HBSS and suspended in PBS supplemented with 1% Foetal Calf Serum
(PAA), 25 mM HEPES and 1 ng/μl of propidium iodide (PI, BD Pharmigen). Cells
were ﬂow sorted for YFP and PI ﬂuorescence using a MoFlo XPD (Beckman
Coulter, Fullerton, CA, USA) Flow Cytometer. Fluorescence was detected using a
530/540 ﬁlter, where PI positive cells were excluded and the YFP positive and
negative fractions collected directly into RLT buffer (Qiagen) supplemented with
1% 2-mercaptoethanol (Sigma) for subsequent RNA isolation.
Expression analyses in histological sections. Whole-mount X-gal staining,
immunostaining and in situ hybridisation on 4–6 µm parafﬁn sections were per-
formed as previously described27. At least three pituitaries or tumours and between
two to six non-consecutive slides were analysed. As negative controls, sections were
hybridised with sense riboprobes for in situ hybridisation or secondary antibody
alone for immunohistochemistry/immunoﬂuorescence. A list of the antibodies and
the antigen retrieval methods used is presented in Supplementary Data 1.
EdU labelling. Pregnant females were injected intra-peritoneally with 100 mg/kg of
EdU and embryos dissected 90 min later. After histological processing and sec-
tioning (see above), double immunostaining for β-catenin and EdU was conducted
using the Click-It EdU imaging kit (Invitrogen) according to the manufacturer’s
instructions.
RNA extraction and cDNA generation. Flow sorted cells from Sox2CreERT2/+;
Ctnnb1lox(ex3)/+;ROSA26YFP/+ and Sox2CreERT2/+;ROSA26YFP/+ mice were pro-
cessed for total RNA extraction using the RNeasy Micro kit (Qiagen). In total, 5 μl
of eluted RNA was then ampliﬁed using the Ovation Pico WTA V2 kit (NuGEN),
followed by puriﬁcation of the resultant cDNA using the QIAquick PCR pur-
iﬁcation kit (Qiagen). Pituitaries from Hesx1Cre/+;Ctnnb1lox(ex3)/+ and control lit-
termates were dissected at 18.5 dpc. The posterior lobe of the pituitary was
discarded and the intermediate and anterior lobes were processed for total RNA
extraction using the RNeasy Micro kit (Qiagen). Approximately 1 μg of total RNA
was reverse transcribed to cDNA using the Transcriptor First Strand cDNA
Synthesis Kit and random hexamers (Roche).
Quantitative real-time PCR and RNA-seq. Quantitative real-time PCR reactions
were run in triplicate using the iTaq SYBR Green (BIORAD) and replicated using a
minimum of four independent samples for each genotype. Primer sequences are
included in Supplementary Data 5. For Shh, we used the Qiagen QuantiTect Primer
Assay (Cat. no. 249900). Results were analysed using the ΔΔCt method. For
RNA-Seq of Sox2CreERT2/+;Ctnnb1lox(ex3)/+;ROSA26YFP/+ and Sox2CreERT2/+;
ROSA26YFP/+ ﬂow-sorted YFP+ cells, isolated RNA was processed by the
SMARTer V4 low input assay kit (Clontech) to generate ampliﬁed cDNA using the
strand-switching protocol. Library preparation was performed with 200 pg of
ampliﬁed cDNA using the Nextera XT preparation kit with 12 cycles of PCR.
Sequencing was then performed on an Illumina NextSeq 500 with 43 bp paired end
reads. Sequencing data was then aligned in BaseSpace. FASTQ and BAM ﬁles are
available on Array Express (E-MTAB-5538), Differential expression was performed
using DESeq267. For GSEA, genes were ranked by the Wald statistic and GSEA
performed using the pre-ranked tool in GSEA v2.2 (Broad Institute)68. The
WNT pathway gene set was downloaded from the hallmark molecular signatures
database v5.2 (Broad Institute)68.
Analysis of the relationship between murine and human ACP. To explore the
relationship between the ACP models and human ACP, gene sets of the 100 and
500 most upregulated genes in human ACP were generated and GSEA performed
as above. In addition, expression data (normalised counts or intensity values) of
11,347 genes, for which expression data was available between non-cluster and
cluster cells from human ACP (array express accession no: E-MTAB-5266),
Sox2CreERT2/+;Ctnnb1lox(ex3);R26YFP/+ tamoxifen-induced mice (E-MTAB-5538)
and Hesx1Cre/+;Ctnnb1lox(ex3)/+ (E-MEXP3492) animals were median scaled and
merged. Clustering was performed using Spearman’s correlation and Ward’s
algorithm.
Exome sequencing of mouse tumours. Fully developed pituitary tumours and
matched tail samples of 15 Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice were collected at
humane end-points. DNA was extracted using the DNeasy bloods and tissue kit
(Qiagen) and exonic DNA was captured using the Agilent whole exome capture kit
(SureSelect Mouse All Exon). Captured material was indexed and sequenced on the
Illumina platform at the Wellcome Trust Sanger Institute at 30× depth. Raw pair
end sequencing reads were aligned with BWA-mem to the GRCm38 mouse
reference genome. Duplicated reads were marked using biobambam. Somatic
variants were detected using CaVEMan, an expectation maximisation-based
somatic substitution-detection algorithm. Detected somatic variants were then
ﬁltered using an array of quality ﬁlters and common mouse genome variants were
excluded69, 70. A sub-selection of 14 genes, where mutant variant allele frequencies
were greater than 20% and at least three mutant reads were detected, were validated
by Sanger sequencing. Primer were designed in ﬂanking regions (Supplementary
Data 2). Sequencing of the PCR fragments was performed by Source BioScience
(UK).
Semi-quantitative ELISA cytokine arrays. Mouse C1000 cytokine arrays (AAM-
CYT-1000-4, RayBiotech) were used to quantify the expression of SASP factors in
protein extracts from whole pituitaries dissected at 18.5 dpc according to manu-
facturer’s instructions (sex was not determined in the embryos). For each experi-
mental sample, total protein was extracted from four pituitaries using the cell lysis
solution provided in combination with a TissueRuptor (Qiagen) and passed
through a Qiashredder column (Qiagen). Total protein was then measured using
BradfordUltra reagent (Expedeon). ELISA membranes were blocked for 30 min
using blocking buffer provided by the manufacturer and then incubated overnight
at 40 °C with 70 μg of total protein. Following extensive washes, membranes were
incubated with biotinylated antibodies and developed according to manufacturer’s
indications. Chemiluminescence detection was conducted with a ChemiDoc gel
documentation system (BioRad) and imaged using ImageLab Software (Version
5.2.1, BioRad). Analysis of high-resolution images from each membrane was
conducted using Fiji/ImageJ and the Protein Microarray Analysis macro (IRB,
Barcelona). Calculation of fold changes in expression was conducted according to
manufacturer’s instructions.
Assessment of clonogenic potential. Anterior pituitaries were dissected and
enzyme treated as described for ﬂow-activated cell sorting, above. This was fol-
lowed by mechanically dissociation into a single-cell suspension and subsequent
washing in Hank’s Balanced Salt Solution. Cells were placed directly into Adherent
Pituitary Stem Cell medium (DMEM-F12; Gibco) containing 5% Foetal Calf Serum
(PAA), 20 ng/ml bFGF (R&D Systems) and 50 ng/ml cholera toxin (Sigma). Cells
were plated into six-well plates at a density of 1000, 2000 and 4000 cells per well for
drug or vehicle treated. After seven days in culture, adherent colonies were ﬁxed,
washed with PBS and stained using Meyer’s Haematoxylin (Sigma) for 10 min and
counted manually.
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Ex vivo culture of mouse pituitaries and ABT-737 treatment. For ex vivo
pituitary culture, anterior pituitaries were isolated from Hesx1Cre/+;Ctnnb1lox(ex3)/+
embryos at 18.5 dpc, placed on top of 0.2 µM Whatman ﬁlters (SLS) in 24 well
plates containing 500 µl of media (DMEM-F12 (Gibco), 1% Pen/Strep (Sigma) and
1% FBS (PAA) supplemented with either ABT-737 at 2.5 µM (Adooq Bioscience),
ABT-263 at 1 µM (Caymen Chemical) or vehicle. Anterior pituitaries were cultured
for 3–4 days, changing media every day and subsequently processed for histological
analysis.
Statistical analyses. Results are presented as means ± s.e.m. unless otherwise
indicated. One-tailed Student’s t test was performed to compare the means of two
groups. Signiﬁcance was assumed at P< 0.05. Sample size varied, but a minimum
of three biological replicas were used for analysis. Statistical analyses were per-
formed using GraphPad software. No samples were excluded from analyses. No
formal blinding or randomisation was used.
Code availability. Codes are available upon request
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